Revolution Medicines (NASDAQ:RVMD) Posts Quarterly Earnings Results, Beats Estimates By $0.45 EPS

Revolution Medicines (NASDAQ:RVMD) posted its earnings results on Wednesday. The company reported ($1.90) earnings per share for the quarter, beating the consensus estimate of ($2.35) by $0.45, FiscalAI reports. The firm had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million.

Here are the key takeaways from Revolution Medicines’ conference call:

• RASONQUE generated $197.6 million in net product revenue during roughly five weeks of U.S. commercialization, with more than 5,000 patients treated commercially and prescribing across academic and community settings. Management cautioned that early demand included finite expanded-access transitions and patients awaiting approval, so the initial results do not yet indicate the launch’s normalized trajectory.
• RASONQUE received a positive opinion from the European Medicines Agency’s CHMP, with a European Commission decision still pending, and NCCN added it as a preferred subsequent-therapy option in pancreatic cancer; the guideline also addresses settings beyond the FDA-approved indication. The company said more than 90% of U.S. pancreatic-cancer covered lives were represented by plans with reimbursed claims, although formal payer policies are still developing.
• Revolution advanced its pivotal pipeline: U.S. enrollment is complete in the first-line pancreatic cancer RASolute 303 study, global enrollment is expected to finish in the first half of 2027, and the RASONQUE–zoldonrasib doublet trial began dosing. It also initiated first-line lung cancer studies and is starting a global Phase III colorectal cancer trial, with BeOne funding and conducting that study.
• R&D and SG&A expenses rose to $417.1 million and $153.3 million, respectively, contributing to a quarterly net loss of $407.5 million. The company reiterated 2026 GAAP operating-expense guidance of $2.1 billion–$2.2 billion and expects expenses to increase in 2027 as it expands development and commercialization spending.

Revolution Medicines Price Performance

Shares of RVMD stock traded up $5.47 during trading hours on Wednesday, hitting $199.70. 2,528,849 shares of the company’s stock were exchanged, compared to its average volume of 2,784,084. Revolution Medicines has a fifty-two week low of $58.00 and a fifty-two week high of $224.31. The firm has a market cap of $42.80 billion, a P/E ratio of -22.64 and a beta of 1.44. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $198.21 and a two-hundred day moving average of $156.90.

Wall Street Analysts Forecast Growth

Several analysts recently commented on RVMD shares. UBS Group raised their price target on shares of Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, August 28th. TD Cowen reiterated a “buy” rating and issued a $250.00 price objective on shares of Revolution Medicines in a research report on Wednesday, October 21st. William Blair initiated coverage on shares of Revolution Medicines in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Bank of America lowered their target price on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a research note on Friday, October 9th. Finally, Sanford C. Bernstein raised their target price on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $242.90.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 13,988 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $2,786,969.12. Following the completion of the transaction, the insider directly owned 253,342 shares in the company, valued at approximately $50,475,860.08. This represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 4,053 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $807,519.72. Following the transaction, the chief financial officer directly owned 119,216 shares in the company, valued at approximately $23,752,595.84. The trade was a 3.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 290,991 shares of company stock worth $59,422,765 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with RAS-mutant cancers. The company’s research platform is designed to discover and develop medicines that inhibit RAS proteins, which play a central role in the growth and spread of many cancers and have historically been difficult to target.

Its investigational pipeline includes RAS(ON) inhibitors and other precision oncology candidates, including daraxonrasib (RMC-6236), a pan-RAS inhibitor being evaluated in multiple solid tumors, as well as programs directed at specific mutations such as KRAS G12C and KRAS G12D.